Immunity Pharma
Compounds for Treating Neurodegenerative Diseases
StartupImmunity Pharma is a Jerusalem-based startup in the Health Tech & Life Sciences sector, established in 2007. Compounds for Treating Neurodegenerative Diseases. The company has 1-10 employees. Core technologies: Biologicals, Cells.
The company follows a B2B business model. Product stage: Clinical Trial.
- StagePre-Funding
- ProductClinical Trial
- ModelB2B
- Employees1-10
- HQJerusalem
- DistrictJerusalem District
- Last RoundUndisclosed
3 articles covered by sources including www.prnewswire.com,
en.globes.co.il,
www.timesofisrael.com.
What does Immunity Pharma do?
Immunity Pharma (IPL) develops therapies for neurodegenerative diseases with an initial focus on amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. IPL's drugs are peptides with biologic activity. The peptides stimulate therapeutic cell-signaling processes that are often down-regulated in neurodegenerative diseases. The drugs mitigate disease progression by inducing survival-supporting processes, including reduction of inflammation and reduction of programed cell death (apoptosis). The lead drug, IPL344, is currently entering an open-label, phase-1/2a clinical trial with ALS patients. IPL344 originates from the research laboratory of Professor Irun Cohen at the Weizmann Institute of Science, Israel.
What sector is Immunity Pharma in?
Immunity Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is Immunity Pharma located?
Immunity Pharma is based in Meron Street 28, Jerusalem, Israel, Jerusalem District.